about
Outcomes in patients with relapsed or refractory multiple myeloma in a phase I study of everolimus in combination with lenalidomide.The association of diabetes and anti-diabetic medications with clinical outcomes in multiple myelomaEfficient allocation of novel agents in multiple myeloma: a work in progressDiscovering discovery patterns with Predication-based Semantic Indexing.Gamabufotalin triggers c-Myc degradation via induction of WWP2 in multiple myeloma cells.JAK2 mutants (e.g., JAK2V617F) and their importance as drug targets in myeloproliferative neoplasmsNovel therapeutic strategies in multiple myeloma: role of the heat shock protein inhibitors.Novel anticancer agents for multiple myeloma: a review of the evidence for their therapeutic and economic value.Real-world health care costs of relapsed/refractory multiple myeloma during the era of novel cancer agents.Heterogeneity of neuroblastoma cell lines in insulin-like growth factor 1 receptor/Akt pathway-mediated cell proliferative responses.Combination of bendamustine and entinostat synergistically inhibits proliferation of multiple myeloma cells via induction of apoptosis and DNA damage response.Anti-Notch treatment prevents multiple myeloma cells localization to the bone marrow via the chemokine system CXCR4/SDF-1.Heat shock protein 90B1 plays an oncogenic role and is a target of microRNA-223 in human osteosarcoma.Autocrine insulin-like growth factor 1 and stem cell factor but not interleukin 6 support self-renewal of human myeloma cells.Analysis of the anti-proliferative and the pro-apoptotic efficacy of Syk inhibition in multiple myeloma.Cladribine and bendamustine exhibit inhibitory activity in dexamethasone-sensitive and -resistant multiple myeloma cells.Inflammatory and Anti-Inflammatory Equilibrium, Proliferative and Antiproliferative Balance: The Role of Cytokines in Multiple Myeloma.
P2860
Q33414827-3CC778AC-4B1B-4C7A-9B99-220C683D8EC6Q33994341-30288D0E-C58C-4726-90D1-1FA84A057C59Q36565638-E93DCBAA-7E1F-438E-BCE3-0BA96587287DQ36664500-86FCE5F8-981E-4847-A5C7-CBEC7526C411Q37085867-993CB993-A11A-4842-897E-7EC20A4C2521Q37168138-C3276989-9567-42EC-BC34-66A500DB7EE6Q37813152-30831768-111F-4CCB-9D9E-1CF917C6FF2DQ38020248-1D38419C-4178-4266-86CE-70F9BC60A9BAQ38057768-185CBDF1-81D6-4F0B-B67A-EC81EB31B055Q39147077-806B2118-93A1-4C0E-9BF7-AE4EC35CD202Q39185574-B5CD9CF2-D146-4E43-8F12-D45691F75D18Q39203918-B22303ED-05C3-4B9C-B40B-2B36E78B8C53Q39233292-BA1DD2C9-F797-4147-9E96-CC4CEC810F48Q41360812-3696FE7A-88FA-4E0C-BFBD-A2C86383C688Q42182953-A3839D0E-5861-4EF3-8712-F41ADCC9760BQ43103345-DB5EBC68-3E6E-4FE6-8F4A-D39A62B49E06Q45756098-B3EC1E27-FAC1-4F3A-AFA0-BD04A8D79661
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on March 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Novel therapeutic targets for multiple myeloma.
@en
Novel therapeutic targets for multiple myeloma.
@nl
type
label
Novel therapeutic targets for multiple myeloma.
@en
Novel therapeutic targets for multiple myeloma.
@nl
prefLabel
Novel therapeutic targets for multiple myeloma.
@en
Novel therapeutic targets for multiple myeloma.
@nl
P2093
P2860
P356
P1433
P1476
Novel therapeutic targets for multiple myeloma.
@en
P2093
Anuj Mahindra
Diana Cirstea
Noopur Raje
P2860
P304
P356
10.2217/FON.10.2
P407
P577
2010-03-01T00:00:00Z